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Abstract
Background: Assessment of malaria endemicity at different altitudes and transmission intensities, in the era of
dwindling vector densities in the highlands, will provide valuable information for malaria control and surveillance.
Measurement of serum anti-malarial antibodies is a useful marker of malaria exposure that indicates long-term
transmission potential. We studied the serologic evidence of malaria endemicity at two highland sites along a
transmission intensity cline. An improved understanding of the micro-geographic variation in malaria exposure in
the highland ecosystems will be relevant in planning effective malaria control.
Methods: Total IgG levels to Plasmodium falciparum MSP-119 were measured in an age-stratified cohort (< 5, 5-14
and ≥ 15 years) in 795 participants from an uphill and valley bottom residents during low and high malaria
transmission seasons. Antibody prevalence and level was compared between different localities. Regression analysis
was performed to examine the association between antibody prevalence and parasite prevalence. Age-specific
MSP-119 seroprevalence data was fitted to a simple reversible catalytic model to investigate the relationship
between parasite exposure and age.
Results: Higher MSP-119 seroprevalence and density were observed in the valley residents than in the uphill
dwellers. Adults (> 15 years) recorded high and stable immune response in spite of changing seasons. Lower
responses were observed in children (≤ 15 years), which, fluctuated with changing seasons particularly in the valley
residents. In the uphill population, annual seroconversion rate (SCR) was 8.3% and reversion rate was 3.0%, with
seroprevalence reaching a plateau of 73.3% by age of 20. Contrary, in the valley bottom population, the annual
SCR was 35.8% and the annual seroreversion rate was 3.5%, and seroprevalence in the population had reached
91.2% by age 10.
Conclusion: The study reveals the micro-geographic variation in malaria endemicity in the highland eco-system;
this validates the usefulness of sero-epidemiological tools in assessing malaria endemicity in the era of decreasing
sensitivity of conventional tools.
Background
Malaria still thrives in the African highlands, in spite of
low vector density exposure [1]. The western Kenya
highlands are an area of particular interest based on the
fact that on a relatively small spatial scale, there is con-
siderable variation in altitude, water accumulation, and
land-use patterns. As a consequence, the epidemiology
of malaria varies markedly. For example, small differ-
ences in altitude have been noted to lead to large
differences in suitability and availability of vector breed-
ing habitats, and consequently, differing risks of malaria
transmission and prevalence [2,3]. These patterns of
malaria reflect heterogeneities in vector distribution,
human vector-contact, and human host factors [4].
Identified risk factors for malaria transmission include
distance to known mosquito breeding sites [5,6], house-
hold construction methods [7], and personal protection
measures against mosquito bites [8]. Moreover, altitude
and environmental landscape, i.e., topography have also
been correlated with risk of malaria infection [2,4,9-11].
Assessing variation in malaria endemicty at different
altitudes across regions with differing malaria
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determining exposure to malaria-infected mosquitoes,
the entomological inoculation rate (EIR) [12], or indir-
ectly by evaluating serological evidence of malaria expo-
sure in the human population [13,14]. Direct measure of
the EIR becomes difficult when absolute numbers of
mosquitoes and sporozoite rates are low, particularly
when EIR is below the detection limits of commonly
used trapping methods [15,16]. The situation is further
complicated when the mosquito densities show marked
heterogeneity, because spatial and temporal variations in
mosquito densities necessitates long-term intensive and
extensive sampling to be accurate [15-17]. Direct deter-
mination of malaria parasitep r e v a l e n c ei nt h eh u m a n
population as an indicator of malaria transmission
intensity has limited sensitivity when transmission is low
[18-20], furthermore, the sensitivity of the tools used in
routine detection of parasitemia; microscopy and
PfHRP2 based rapid diagnostic test (RDTs) presents
additional challenges at low parasite densities.
Prevalence of antibodies to Plasmodium falciparum
has been explored as a marker of human exposure to
malaria [13,14,21-24]. Measurement of serum antibodies
is a useful index of malaria transmission intensity when
the focus is on evaluation of malaria exposure over
time, since anti-malarial antibodies develop after
repeated exposures and can persist for months to years
after infection [14]. Seroprevalence reflects cumulative
exposure and thus it is less affected by seasonality or
unstable transmission due to the longer duration of the
specific antibody response. Additionally the longevity of
antibody response generates a seroprevalence that is
higher than equivalent parasite rates, making it a more
sensitive measure. Therefore, immunological markers
may be useful to detect malaria exposure in areas of low
endemicity [21,24]. Seroconversion rates are related to
the force of infection of malaria as refracted through the
immune responses of exposed individuals [24-26]. Thus
the seroconversion rates provide measures of malaria
exposure that compares with the malaria transmission
intensity [13,14,27]. Additionally, antibody responses
have been shown to have a tight correlation with EIR
and offer the potential to detect recent changes in
malaria transmission intensity [13,14,27].
However, the use of inadequate serological markers
may underestimate exposure by virtue of their lack of
sensitivity. For instance, in the case of circumsporozoite
protein (CSP), sporozoites injected by infected mosqui-
toes have a relatively short life-span in the blood. Some
rapidly develop into liver stages and others are taken up
by macrophages, processed, and presented to the
immune system [23]. The amount of antigenic material
and the time of contact with immuno-competent cells
are relatively shorter than blood stage antigens and thus
may underestimate malaria exposure in low transmis-
sion settings. Druilhe and others could not detect CSP
antigens in children in low transmission area even
though 78% of them had detectable blood stage anti-
gens, and from these data, they concluded that CSP is
not a reliable marker of malaria endemicity when the
total EIR in the area is less than 10 infectious bites per
person per year [28]. In hyperendemic areas, however,
CSP has been reported to give reliable estimates of
malaria endemicity and reflects the seasonal dynamics of
transmission [23,29] and may be sufficiently sensitive to
evaluate the protective efficacy of anti-vector devices in
transiently exposed travelers to endemic countries [30].
On the other hand, surface proteins of merozoites like
apical merozoite antigen-1 (AMA1), are highly immuno-
genic and tend to saturate detectable antibody responses
in the population in low to moderate transmission set-
tings. Alternatively, Drakeley and others [14] described
MSP -119 as the most suitable immunological marker
for assessing malaria endemicity at varying altitudes
along transmission intensity cline.
MSP-1 is secreted as a 195-kDa precursor anchored
via glycosylphosphatidylinositol [31]. This is cleaved by
proteases into fragments of 83, 28-30, 38-45 and 42 kDa
[32]. During merozoite invasion, the 42 kDa fragment
(MSP-142)i sf u r t h e rc l e a v e dt op r o d u c ea3 3 - k D af r a g -
ment (MSP-133) and a 19 kDa C-terminal fragment
(MSP-119); with the later remaining attached to the mer-
ozoite surface and present on ring forms in newly
invaded erythrocytes [33]. MSP-119 is thus a recognized
target of protective immunity [34].
This study was therefore conducted to investigate ser-
ologic evidence of malaria exposure at a highland site
along a malaria transmission intensity cline to character-
ize differences in malaria endemicity. The current study
reports an improved understanding of the micro-geo-
graphic variation on malaria endemicity in the complex
highland eco-system; and potentially identifies vulner-
able groups in the event of hyper-transmission. This
study confirms that sero-epidemiology provides valuable
information for planning effective malaria control strate-
gies and surveillance systems.
Methods
Study site
The study areas included two highland sites located in
Iguhu and Lidambiza villages (0°10’N, 34° 44’E, elevation
1,420-1,500 m above sea level [asl], defined as valley
bottom site), and Sigalagala and Museno villages (0°
33’N, 34° 47’E, elevation 1,520-1,600 m [asl], defined as
uphill site), all in Kakamega county, western Kenya. The
terrain of the study area is typical of the highlands and
consists of hills and river valleys. The hillside is mostly
dotted with maize fields and subsistence crops. Six
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study villages and empty into the main Yala River,
which runs through the area from east to west. The
inhabitants live in houses of stick frames with mud
walls and thatch or corrugated metal roofs. The area
experiences two rainy seasons, and averages 2,000 mm
rainfall per year. The long rainy season typically occurs
between April and May, with an average monthly rain-
fall of 150-260 mm, while the short rainy season typi-
cally occurs between September and October, with an
average monthly rainfall of 165 mm. The main dry sea-
son occurs from December to March [35]. The mean
annual daily temperature is 20.8°C. Malaria prevalence
peaks usually 1-2 months after the onset of the rains.
Malaria vectors in the area are Anopheles gambiae sensu
stricto and A. funestus, [4,36]. Most mosquito larval
habitats are found on riverbanks in the bottom of the
valley and on the banks of streams during both dry and
rainy seasons. Adult mosquito population thus tends to
cluster around the valley bottom, where about 90% have
been found within a distance of 300 meters of the
breeding sites at the valley bottom [4,35,37].
Study participant and blood collection
A serological cross-sectional survey was carried out dur-
ing the dry season in February-March 2009, and again
in the rainy season in June-July of the same year, corre-
sponding to the low and high transmission seasons,
respectively. To obtain informed consent, residents in
individual, randomly selected households were
approached, the study goals and procedures were
explained and potential participants were invited to
enroll in the study. All willing individuals signed consent
forms or provided a thumbprint in the presence of wit-
nesses. Parental consent was obtained for children and
all participants were transported to the Iguhu district
government hospital. Individuals of all age groups from
the study sites were eligible to participate except infants
of less than 6 months of age. Demographic data includ-
ing age and gender were taken, and, as altitude was a
critical feature of the study, participants were also
required to confirm their village of residence. Subse-
quently, clinicians and nurses obtained venipuncture
blood (~ 3 ml). Sera was isolated and transported to the
Kenya Medical Research Institute (KEMRI) Kisumu
laboratories for storage in freezers at -80°C until further
processed. Thick and thin blood smears were prepared
according to standard protocols described elsewhere
[38], to determine parasite prevalence. All individuals
presenting with fever and parasitemia were given free
malaria treatment by a clinician according to Kenya gov-
ernment guidelines, and children under the age of five
were also given free ITNs as per Ministry of Health pol-
icy. The study was approved by the Kenya Medical
Research Institute Ethical Review Committee [SCC No.
1382(N)] and the Institutional Review Board of the Uni-
versity of California, Irvine.
Measurement of specific humoral responses
The expression and purification of the PfMSP-119 FVO
recombinant protein has been described elsewhere
[39,40]. Total IgG responses to PfMSP-119 FVO specific
antigen were measured in serum by indirect ELISA [27].
Briefly, plates were coated with 0.2 μg antigen in 100 μl
of 1xPBS, and incubated overnight at 4°C. After block-
ing with 0.5% casein, 0.05% Tween 20, test sera were
serially diluted in triplicate on the plates from 1:50 to
1:64,000 and incubated for 2 h at 22°C, followed by
horseradish peroxidase-conjugated goat anti-human IgG
(KPL, Gaithersburg, MD) for 1 h. After the addition of
ABTS peroxidase substrate (Kirkegaard & Perry Labora-
tories Inc., Gaithersburg, MD), plates were incubated for
1 h, at 22°C and the reaction stopped by addition of 10
μlo f2 0 %S D S( S i g m a ,S t .L o u i s ,M O ) .P l a t e sw e r e
washed 4 times between each step. Plates were read at
414 nm with the SPECTRAMAX 340pc (Molecular
Devices Corporation, Sunnyvale, USA) and the serial
dilutions were used to fit a four-parameter curve using
SoftMax Pro v4.1 (Molecular Devices). Results were
expressed in titer values, the titer endpoint being
defined in this study as the calculated serum dilution
yielding an optical density of 1.0. A serum pool obtained
from 30 naïve US donors never exposed to malaria was
used to define an assay cutoff; the mean titer +3 SD
represented the cutoff value for all negative responses to
the PfMSP-119 antigen. The resultant titer value
obtained as cutoff was 63.3; any titer above this value
w a sc o n s i d e r e da sp o s i t i v e .Ap o o lo fm a l a r i ap o s i t i v e
individuals from hyper-endemic areas in Kenya was
used for positive controls.
Statistical analysis
MSP-119 seroprevalence is the number of positive
responders out of the totaln u m b e ro fp a r t i c i p a n t s
tested; this is simply referred to in the whole text as ser-
oprevalence. Differences in the proportion of seropreva-
lence of MSP-119 between age-stratified, uphill and
valley residents were compared by the c
2 test with p <
0.05 considered statistically significant. The Mann-Whit-
ney test was used to test if medians of seroprevalence
were different between localities. Multinomial logistic
regression was used to examine the association between
MSP-119 seroprevalence and parasite prevalence adjust-
ing for age in the valley and uphill population. Linear
regression was used to examine the trend of parasite
prevalence and age at different localities
We fitted age specific MSP-119 seroprevalence data to
a simple reversible catalytic model using the maximum-
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bution;
Pt =
λ
λ + ρ

1 − e−(λ+ρ)

where Pt is the proportion of individuals aged t that is
seropositive, constant l is the annual rate of seroconver-
sion and r is the annual rate of reversion to seronega-
tive. This was done to investigate the relationship
between force of parasite exposure and age [14]. For
PfMSP-119 antibody titer, the data were analyzed and
graphed using GraphPad Prism software (San Diego,
C A ,U S A ) .T h ea g e - s e r o p r e v a l e n c em o d e lw a sf i t t e d
using JMP 9.0 (SAS, Cary, NC 27513, USA).
Results
Study population
The distribution of the participant’sp o p u l a t i o ni nt e r m s
of age and locality are shown in Table 1
Parasite prevalence
In Figure 1, generally, age-parasite prevalence trends
correlated negatively with each other. In the uphill resi-
dents, significant age-related parasite prevalence was
observed where parasite prevalence decreased with
increasing age (R
2 = 0.52, p = 0.02). A similar trend was
observed in the valley bottom residents where parasite
prevalence generally declined with increasing age, how-
ever, this was marginally significant (R
2 =0 . 4 0 ,p =
0 . 0 5 ;F i g u r e1 ) .T h e r ew e r em a r k e dd i f f e r e n c e si np a r a -
site prevalence between uphill and valley residents.
These differences were significant in the < 5 and 5-14
years age groups, (c
2=3.93, df = 1, p = 0.047) and (c
2
= 9.26, df = 1, p = 0.002) respectively. In these two
groups we observed parasite prevalence as high as a 2-
fold increase in the valley residents compared with the
uphill residents. However in the adult group we
observed no significant differences in parasite preva-
lence between uphill and valley residents (c
2 = 1.93, df
=1 ,p = 0.164).
Variation of MSP-119 seroprevalence with age, season,
and altitude
In Table 1 when the two sites were considered indepen-
dently, there was significant variation in seroprevalence
with age for both sites during both seasons; proportions
of seropositive individuals increased significantly with
increasing age. Seasonal variation was generally observed
at both localities; however, it was only in the valley bot-
tom area where significant seasonal variation in seropre-
valence was observed in the 5-14 years age group.
Furthermore, highly significant differences were found
when seroprevalence was compared between the uphill
and valley residents in both seasons (dry season c
2 =
33.78, df = 1, p < 0.001, rainy season c
2 =6 9 . 9 6 ,d f=1 ,
p < 0.001). However, when the two sites were combined
there was no significant inter-seasonal variation in sero-
prevalence in < 5 and ≥ 15 years age groups (p =0 .1 7 0
and p = 0.190, respectively). In contrast, the seasonal
variation in seroprevalence was significant in children
within the 5-14 years age group (c
2 = 10.73, df = 1, p =
0.001).
Spatiotemporal variation in total IgG titers
Analyses of median IgG titer levels among the study
population revealed a13-fold higher titer levels in resi-
dents at the valley bottom compared to the uphill
Table 1 MSP-119 seroprevalence (%) in different age groups stratified according to season and locality in western
Kenya Highland
Uphill Valley
Season < 5
(n = 88)
5-14
(n = 174)
≥ 15
(n = 143)
c
2-value** P <5
(n = 83)
5-14
(n = 151)
≥ 15
(n = 160)
c
2-value** P
Dry 27.50 36.70 75.00 30.34 < 0.001 60.00 70.00 98.40 45.59 < 0.001
Rainy 25.00 49.10 64.80 17.21 < 0.001 71.20 87.10 90.70 11.56 0.003
c
2-value* 0.067 2.402 1.770 1.007 6.496 3.686
P 0.794 0.120 0.180 0.315 0.010 0.054
* Comparison between seasons, df = 1 for all tests
** Comparison among different age groups, df = 2 for all tests
y=Ͳ0.232x+17.055
R²=0.3972
y=Ͳ0.0651x+6.5299
R²=0.5262
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Figure 1 Scatter graph showing trends of parasite prevalence
with age in the uphill and valley populations.
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(Figure 2). Generally, increasing MSP-119 seroprevalence
correlated positively with increasing relative antibody
levels; in the Uphill population (R
2 =0 . 8 4 7 ,p < 0.001,)
and in the valley population (R
2 =0 . 6 2 3 ,p =0 . 0 1 1 ) .
Adjusting for age, the multinomial logistic regression
used to assess the association between MSP-119 seropre-
valence and parasite prevalence, revealed that seroposi-
tive individuals were more likely to have been exposed
to parasites compared to seronegative individuals (Table
2). This was true, both in the uphill and valley residents.
Age-dependent antibody acquisition model
A simple catalytic model showed that seroconversion
and seroreversion rates were highly age-dependent (Fig-
ure 3). In the uphill population, the annual seroconver-
sion rate was 8.3% and reversion rate was 3.0%, with
seroprevalence reaching a plateau of 73.3% by the age of
20 years (probably due to less frequent exposure to
parasite infection). In contrast, the valley bottom
population annual seroconversion rate was 35.8% and
annual seroreversion rate was 3.5%, and by 10 years of
age 91.2% of the population already had antimalarial
antibodies (Figure 3).
Discussion
Using age-specific MSP-119 seroprevalence, seroconver-
sion rates (SCR), and total IgG titers, together with
malaria infection prevalence, we have observed consider-
able variation in human exposure to malaria in western
Kenya. Seroprevalence of residents at the valley bottom
was almost two fold higher than that of the uphill resi-
dents. Comparison of the median total IgG titers in the
study population revealed a13-fold difference between
the uphill and valley bottom residents. Similar trends
have been observed in entomological and parasitological
studies, which have consistently found higher transmis-
sion intensity, vector abundance, and parasite prevalence
at the valley bottom, in comparison to the top of the
hill [4,17,38]. This may partly be explained by the differ-
ences in water accumulation between the two sites, as
the valley bottom residents live along River Yala which
provides permanent breeding habitats for malaria vec-
tors all year round, resulting in a higher risk of exposure
to infected mosquitoes compared to residents uphill
[4,10,17,38].
Immunity to malaria is a function of exposure chal-
lenge; it develops gradually as a consequence of experi-
encing multiple parasite exposures or persistent
infection for years. Consequently, seroprevalence reflects
cumulative exposure and, thus, is less affected by sea-
sonality or unstable transmission due to the longer
duration of the specific antibody response [14,21,41]. It
may be limited in detecting discrete seasonal variation
in transmission but is a good indicator of long term
transmission potential. And antibody persistence gener-
ates seroprevalence that are higher than equivalent
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Figure 2 Differences in IgG titers among different localities. ***
indicates the significance test by Mann-Whitney test, P value <
0.001 (Uphill n = 401, Valley n = 394).
Table 2 Showing the association between MSP-119
seroprevalence with Plasmodium parasite prevalence at
the different localities
Parasite prevalence
MSP-119 seroprevalence
Locality (n) Odds Ratio 95% CI P value
Uphill (401) 2.798 [1.018, 7.693] 0.046
Valley (394) 3.167 [1.196, 8.386] 0.020
Total Uphill and Valley (795) 4.282 [2.200, 8.330] < 0.001
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Figure 3 Kinetics of the age-dependent antibody prevalence at
different altitudes. phill model: Pt = 0.73(1-e
-0.11t), R
2 = 0.95, P <
0.001; valley bottom model: Pt = 0.91(1-e
-0.39t), R
2 = 0.67, P < 0.001.
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oprevalence at this site particularly in the valley resi-
dents indicate possible frequent or persistent exposure
to parasite infection. An earlier study at this same site
reported that, 38.2% of asymptomatic individuals harbor
infections that persist for 2-5 months and a further
14.2% of them harbored asymptomatic infections from
6-12 months [17]. A follow up study revealed high
infection turn-over rate i.e. frequent clearance and
acquisition of infection, with the average infection dura-
tion of single parasite genotypes being 1.1 months, and
the longest genotype persistence being 3 months [10].
Whether these infections are recrudescence or re-infec-
tions they have the ability to maintain seropositivity and
thus lead to acquisition and maintenance of significant
high levels of antimalarial antibody responses. Moreover,
i th a sb e e no b s e r v e dt h a tp e r s i s t e n to re v e ns u b - p a t e n t
infections are sufficient to maintain seropositivity and
partial immunity consistent with the concept of premu-
nition [42].
Age-specific seroprevalence has been used to estimate
seroconversion rates (SCR) as a measure of malaria
transmission intensity. Earlier studies in neighboring
Tanzania have shown that these estimates are tightly
correlated with EIR measurement [13,14,27]. Age sero
-prevalence curves reflect different levels of transmission
intensity. In low transmission settings development of
antibodies is slow and is mainly exhibited by the adult
population, whereas in a high transmission area, much
of the population will be seropositive even at a younger
age [43]. This phenomenon is clearly demonstrated in
our age seroprevalence curves (Figure 3). In the uphill
population the seroprevalence reaches a peak of 73.3%
only at age 20; this is in sharp contrast to that seen in
the valley, where seroprevalence reaches a peak of 91.2%
by the age of 10. These observations reveal the differ-
ence in the intensity of malaria transmission between
the two localities, suggesting a higher intensity of
m a l a r i at r a n s m i s s i o ni nt h ev a l l e ya r e at h a nt h eu p h i l l
area. These findings are further corroborated by other
evidence such as the vector density variation between
valley bottom and uphill in our study site [4,17] and by
the repeated infections observed in the valley area
[10,17].
In very low transmission settings, where parasite pre-
valence and EIR are insensitive, serological measures
offer a way of accurately assessing endemicity and iden-
tifying focal areas of transmission supporting the poten-
tial for elimination [43]. Historically, several studies
have used serology in this context. In determining ende-
micity and evaluating eradication campaigns in Tanza-
nia, repeated cross-sectional serological surveys were
used to assess approximately 1,500 individuals, and the
serological data accurately distinguished between areas
of different transmission intensity [44]. Similarly in Suri-
nam, supporting an elimination program, approximately
2,000 individuals of all ages were serologically assessed;
and the antibody responses in these individuals reflected
the epidemiological situation at the time of sample col-
lection and accurately defined areas which had elimi-
nated malaria [45]. Furthermore, in Mauritius and
Tunisia, immuno-florescent antibody assays (IFAT) were
used to follow reducing seroprevalence over several
years in eradication campaigns until no seropositives
were detected in children under 5 and 15 years, respec-
tively, thus confirming successful eradication [46,47].
When we compared age-specific IgG titers from the
two sites, there was a highly significant difference in the
IgG titers between the valley bottom and the uphill resi-
dents, indicating a considerable variation in malaria
endemicity within the highland area. The observed sea-
sonal variation in the IgG titres in the 5-14 year group
suggests that the level of exposure may not result in the
development of stable humoral responses by the age 14.
If this is solely due to seasonal exposure to malaria
parasites, then it may represent a vulnerable group in
the valley bottom area that may pose a public health
problem in an event of hyper malaria transmission. As
individuals remain seropositive for several years, the
level of antibody response (IgG titers) can reflect fluc-
tuations in recent exposure. It is known [43] that anti-
body levels tend to be higher in actively infected
individuals with a concomitant decline as the parasites
are cleared. This seems to be the case in the less than
15 years age group in the valley who also had highest
parasite prevalence. The valley bottom is characterized
by persistent infections, a single parasite genotype has
been observed to persist for 3 months [10], detailed
examination of IgG titer with age revealed that on the
average, titer level at age 5 in valley is similar to that at
age 20 in uphill (data not shown). This should not be
surprising as at the age of 10 seroprevalence in the val-
ley exceeds 90%.
The observed parasite prevalence in the current study
is lower compared to earlier studies conducted in the
same area [17,40]. Munyekenye and others [43],
reported a mean annual parasite prevalence of 47.0% in
children of 1-9 years and 9.5% in > 19 year olds. Balir-
aine and others [17] using the combination of micro-
scopy and PCR technique observed parasite prevalence
of 34.4%, 34.1% and 9.1% in 5-9, 10-14 and > 15 years,
respectively. The current conducted two cross-sectional
surveys across all age groups of participants, and
observed a mean infection prevalence of 14.0% in < 5
and 5-14 year olds and 6.8% in > 15 years. Consistent
with all these studies is the finding that parasite preva-
lence generally decreases with age and distance from the
valley bottom. Parasite prevalence in adults has not
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ability to clear and suppress parasites through their
acquired immunity or from clearance using antimalar-
ials. On the whole the mean parasite prevalence in the
valley population and that of uphill population were
16.3% and 6.3% respectively. However the equivalent
seroprevalence were 79.56% and 46.34% for valley and
uphill respectively. This implies that looking at parasite
prevalence alone about 84% and 94% of valley and uphill
residents would be considered unexposed. Seroepide-
miology thus presents a more sensitive tool in describ-
ing the malaria endemicity of a population under low to
moderate transmission.
We observed a spectrum of MSP-119 responses that
are highly varied within the same age group and altitude
transects. Other studies have observed similar variation
in exposure, susceptibility and even disease patterns at
the individual level [11,48,49]. This finding may partly
be explained by factors such as host genetic polymorph-
ism, [50], MSP-1 polymorphism [51] or antigenic sin.
Nevertheless, in a population that is predominantly of
one sub-tribe, variation in exposure to mosquito bites is
likely to play an important role [7]. Intrinsically indivi-
dual factors such as household structure, use of ITN [8],
and proximity to breeding sites [15,22] may be impor-
tant determinants of this variation. A follow-up study is
underway to test this hypothesis by testing individual
responses to An. gambiae salivary gland protein (gSG6-
P1) previously validated as a marker of mosquito bite
exposure [52].
Conclusions
MSP-119, a leading vaccine candidate was used as a
marker of immune response and a proxy of parasite
exposure between the valley bottom and uphill resi-
dents. We observed higher immune response to the
Plasmodium falciparum antigen in the valley residents
than in the uphill dwellers indicating a possible higher
exposure to infections. Odds ratios indicated seroposi-
t i v ei n d i v i d u a l sw e r em o r el i k e l yt ob ep a r a s i t ep o s i t i v e
than seronegatives. High and stable humoral immune
responses were observed in older residents (> 15 years)
at our highland site in spite of changing seasons. How-
ever, in children (≤ 15 years) we observed lower
responses that also fluctuated with changing seasons. If
the MSP-119 immune responses reflect functional
immunity, something that was not directly determined
in this study and is currently uncertain, uphill popula-
tions, particularly children ≤ 15 years of age, may be at
a higher risk of (severe) clinical disease. This hypothesis
requires further longitudinal studies.
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